

“Los antiparasitarios orales para perros de Boehringer Ingelheim, Nexgard® y Nexgard SPECTRA®, obtienen nuevas e importantes indicaciones”

Marta León, asesora técnica veterinaria de Pets en Boehringer Ingelheim y especializada en el área de antiparasitarios

Referencias

1. Resumen de las Características de los Productos de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), 2023 Agencia Española de Medicamentos y Productos Sanitarios (aemps.gob.es)
2. Schwartz R, Bidaisee S, Fields PJ, Maxine L, Macpherson A, Macpherson CNL. The epidemiology and control of *Toxocara canis* in puppies. *Parasite Epidemiology and Control* 16 (2022) e00232
3. CVMP assessment report for a variation requiring assessment for NexGard® and NexGard SPECTRA® (EMA/V/C/WS2280/G) EMA/950147/2022
4. Doug Carithers, Jordan Crawford, Christa de Vos, Alta Lotriet and Josephus Fourie. Assessment of afoxolaner efficacy against *Otodectes cynotis* infestations of dogs. *Parasites & Vectors* (2016) 9:635
5. CVMP assessment report for a variation requiring assessment for NexGard® and NexGard SPECTRA® (EMA/V/C/WS2280/G) EMA/950147/2022
6. Rossella Panarese, Roberta Iatta, Riccardo Paolo Lia, Wilfried Lebon, Frederic Beugnet, Domenico Otranto. Efficacy of afoxolaner (NexGard®) for the treatment of ear mite infestation under field conditions. *Veterinary Parasitology* 300 (2021) 109607
7. Lebon W., Meyer L., Ezzahra Akki, F., Madder M., Beugnet F. Efficacy of a single administration of Afoxolaner (NexGard®) or Fipronil plus Permethrin (Frontline Tri-Act®) against *Hyalomma marginatum* ticks in Dogs. *Veterinary Parasitology: Regional Studies and Reports* 25 (2021) 100606
8. Halos L. et al. Preference of Dogs between Two Commercially Available Oral Formulations of Ectoparasiticide Containing Isoxazolines, Afoxolaner or Fluralaner. *Open Journal of Veterinary Medicine*, 2015, 5, 25-29. 4.
9. Carithers D.S. et al. Comparison of Preference Demonstrated by Dogs When Offered Two Commercially Available Oral Ectoparasiticide Products Containing Either Afoxolaner (NexGard®) or Sarolaner (Simparica™).
10. Perier N, Carithers DS, Everett WR, Gross SJ, Wongnak P, Chalvet-Monfray K, Beugnet F. Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NEXGARD SPECTRA® (Afoxolaner and Milbemycin Oxime) and Simparica Trio (Sarolaner, Moxidectin and Pyrantel). *Open Journal of Veterinary Medicine*, 2020, 10, 155-163. <https://www.scirp.org/journal/ojvm>.

11. Perier N et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard SPECTRA[®] (Afoxolaner and Milbemycin Oxime) and Credelio[®] Plus (Lotilaner and Milbemycin Oxime). Open Journal of Veterinary Medicine, 2021, 11, 289-298.
<https://www.scirp.org/journal/ojvm>.
12. Estudio de mercado realizado por Boehringer Ingelheim en 2021.